Alongside Cambridge Enterprise, an international syndicate of investors joined HexagonFab’s seed investment round. Among them are Parkwalk, New Grounds VC, Silicon Valley-based R42 Group, Swiss Health Angels and several private investors. Proceeds from the seed funding round will allow the company to grow its team, complete the development of the Bolt, and launch it in the market.
High costs and risk of failure limit the discovery and development of next-generation biopharmaceuticals. HexagonFab aims to change this by giving scientists, researchers, and drug manufacturers better analytical tools such as the Bolt. Powered by a graphene-based semiconductor sensor, the Bolt can detect proteins, antibodies, and small molecules down to a low nanomolar concentration, irrespective of their molecular weight or size. The Bolt can rapidly generate data on critical parameters during the R&D and production of biopharmaceuticals. It does not require installation.
The Bolt allows scientists and researchers in drug discovery and plant managers or quality control staff in pharmaceutical manufacturing facilities to perform the necessary tests on-site. With a real-time signal enabling the observation of binding events and measurement of binding affinity, the results are available in hours instead of days.
“Many researchers would like to get molecular binding data more conveniently and more frequently to guide them through a drug development project. HexagonFab aims to address this need with the Bolt. This investment will enable us to bring our game-changing product to the market. We look forward to the months ahead working closely with our lead customers,” said Christoph von Bieberstein, Founder and Commercial Director of HexagonFab.
Born Global with an international team
While its headquarters are currently in the UK, HexagonFab has a strong foothold in Switzerland with its commercial offices at the Impact Hub in Zurich. Commercial Director and Founder Christoph von Bieberstein, a former student at the University of St. Gallen, is based in Switzerland and is supported by multiple employees. Its second founder and the company's Technical Director Ruizhi Wang, a former student at the ETH, and the rest of the employees are based in the UK, where the company has its R&d laboratory.
According to Bieberstein, the decision to establish the company in the UK was supported by the existence of the right infrastructure in the country that would allow for protein analysis. In the near future, however, the company plans to further strengthen its presence in Switzerland where it has already obtained support from Venturelab, Innosuisse among others.